Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure
Most Cited Paper
in Heart Failure Treatment and Management
18 Months Post-Publication
Class of 2026
“Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026/
Topics
Dapagliflozin · Acute decompensated heart failure · SGLT2 inhibitors · Efficacy · Safety · Heart failure with reduced ejection fraction · Heart failure with preserved ejection fraction · Clinical trial design · Cardiovascular events · Heart failure hospitalization · All-Cause Mortality · Cardiovascular death · Natriuretic peptides · Renal function · diuresis · Natriuresis · Glycemic control · Type 2 diabetes · Randomized controlled trial · Patient-reported outcomes · Quality of life · Adverse events · Drug safety · Acute decompensated heart failure · In-hospital initiation of therapy · cardiorenal syndrome · Fluid Overload · Guideline-Directed Medical Therapy · Length of stay · Readmission rates
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026. https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459